Johnson & Johnson: long-term objectives unveiled
At a meeting with the financial community, the US group explained that it aims to grow sales by between 5% and 7% a year over the period 2025 to 2030.
This growth will come from both its innovative medicine and medtech divisions, both of which are expected to grow at a rate of 5%-7% a year.
CEO Joaquin Duato explains that the company intends to capitalize on trends towards more effective and personalized treatments, as well as earlier interventions and less invasive procedures.
For 2024, J&J says it is targeting sales growth of 5% to 6%, with earnings per share (EPS) expected to be between $10.55 and $10.75, taking into account the dilutive effect of the Laminar acquisition ($0.15 per share).
By way of comparison, the consensus had previously been expecting EPS of $10.78.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction